China NMPA Drug Inspection - Hubei Ruizhe Pharmaceutical Co., Ltd. commissioned Hubei Xin"ankang Pharmaceutical Co., Ltd. - Ursodeoxycholic acid tablets
China NMPA drug inspection for Hubei Ruizhe Pharmaceutical Co., Ltd. commissioned Hubei Xin"ankang Pharmaceutical Co., Ltd. published June 20, 2023. Drug: Ursodeoxycholic acid tablets. On June 20, 2023, China’s National Medical Products Administration (NMPA) released Announcement No. 26 of 2023, identify
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hubei Ruizhe Pharmaceutical Co., Ltd. commissioned Hubei Xin"ankang Pharmaceutical Co., Ltd. published June 20, 2023. Drug: Ursodeoxycholic acid tablets. On June 20, 2023, China’s National Medical Products Administration (NMPA) released Announcement No. 26 of 2023, identify
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox